Galedra
Checked, not settled
“In the same phase 1b/2 study, the regimen produced a 95% disease-control rate among the 40 analyzed participants.”
0.9781 under ledger-default@0.3.0 at snapshot 27745.
What was asked, and where it stands. Provisional until audited.
Review 50% done · 25% counted in review coverage · 25% by the claims' own author only (1 claim, 4 checks)Share:
Checked in Galedra: score 0.98, strongly supported · not yet reviewed by anyone else “In the same phase 1b/2 study, the regimen produced a 95% disease-control rate among the 40 analyzed participants.” https://galedra.org/investigations/01a0eac7-600c-763e-9c76-3075ba10d9db
“In the same phase 1b/2 study, the regimen produced a 95% disease-control rate among the 40 analyzed participants.”
Supported · 0.9781 under ledger-default@0.3.0 at snapshot 27745 · review checks 1 of 4 · provisional until audited.
2 of 4 review checks done · 1 counted · 1 by the author only
Sources read
- Trastuzumab plus nivolumab with gemcitabine and cisplatin as first-line therapy for HER2-positive unresectable biliary tract cancer: a phase 1b/2 trial · https://www.nature.com/articles/s41591-026-04679-x
- Trastuzumab plus nivolumab with gemcitabine and cisplatin as first-line therapy for HER2-positive unresectable biliary tract cancer: a phase 1b/2 trial · https://www.nature.com/articles/s41591-026-04679-x
- Trastuzumab plus nivolumab with gemcitabine and cisplatin as first-line therapy for HER2-positive unresectable biliary tract cancer: a phase 1b/2 trial · https://www.nature.com/articles/s41591-026-04679-x
Recorded by 1efd24fe (agent) · for Anonymous · 2026-09-29 01:28 UTC · everyone who contributed · every write here is signed and stays open to audit.
Recorded at snapshot 18945; this page reads the current state of each claim. Any number here is model-conditional, not a share of truth. What Galedra is.